聚肌胞苷酸在免疫制剂中的研究进展  

Research progress of polyinosinic polycytidylic acid in immunopreparations

作　　者：柯丁心 王毅 孙敏 蒋亚君 刘开云 KE Dingxin;WANG Yi;SUN Min;JIANG Yajun;LIU Kaiyun(Institute of Biopharmacy,West China Hospital,Sichuan University,Chengdu 610044,Sichuan Province,China)

机构地区：[1]四川大学华西医院生物制药研究院,四川成都610044

出　　处：《世界临床药物》2023年第11期1219-1225,共7页World Clinical Drug

基　　金：四川大学华西医院学科卓越发展135工程项目(ZYXY21003)。

摘　　要：聚肌胞苷酸是一种人工合成的双链核糖核酸,可被Toll样受体3识别,诱导先天和适应性免疫反应,其通常被认为是一种Ⅰ型干扰素诱导剂、抗病毒和抗肿瘤等免疫调节剂,也是有效的疫苗佐剂,并在疾病治疗中展现出巨大的潜力。因此该文从聚肌胞苷酸的作用机制、安全性及在临床中作为免疫制剂的研究进展等方面进行综述,希望能为其的后续研究提供有益参考。Polyinosinic polycytidylic acid is an artificially synthesized double stranded ribonucleic acid that is recognized by Toll-like receptor 3,induces innate and adaptive immune responses.It is generally considered as a typeⅠinterferon inducer,antiviral and anti-tumor immunomodulator agent,and also an effective vaccine adjuvant,and has shown great potential in the treatment of diseases.Therefore,this article reviewed the regulatory mechanism,safety,and the research progress of polyinosinic polycytidylic acid as an immunologic agent in clinical practice,hoping to provide useful reference for the follow-up research of polyinosinic polycytidylic acid.

关 键 词：聚肌胞苷酸 TOLL样受体3 免疫治疗 疫苗佐剂 

分 类 号：R392[医药卫生—免疫学]